Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?

참고문헌 (7)

1. Tadakazu Hisamatsu, "Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study", Intestinal research, 19(4), pp.408~418 (2021), 대한장연구학회[DOI]
2. Haruhiko Ogata, "Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study", Intestinal research, 19(4), pp.419~429 (2021), 대한장연구학회[DOI]
3. Hiep Phan, "Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy", Intestinal research, 18(3), pp.282~288 (2020), 대한장연구학회[DOI]
4. Eirini Theodoraki, "Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?", Intestinal research, 19(4), pp.461~467 (2021), 대한장연구학회[DOI]
5. Song Joo Hye, "Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study", Gut and Liver, 15(5), pp.752~762 (2021), 거트앤리버 소화기연관학회협의회[DOI]
6. Kobayashi T, "Discontinuation of infliximab in patients with ulcerative colitis in remission(HAYABUSA) : a multicentre, open-label, randomised controlled trial", Lancet Gastroenterol Hepatol, 6, pp.429~437 (2021)
7. Louis E, "Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped", Gastroenterology, 142, pp.63~70 (2012)

관련 논문AI추천